- Home
- EOI vs PRTA Comparison
EOI vs PRTA Comparison
Compare EOI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOI
- PRTA
- Stock Information
- Founded
- EOI 2004
- PRTA 2012
- Country
- EOI United States
- PRTA Ireland
- Employees
- EOI N/A
- PRTA N/A
- Industry
- EOI Finance/Investors Services
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- EOI Finance
- PRTA Health Care
- Exchange
- EOI Nasdaq
- PRTA Nasdaq
- Market Cap
- EOI 746.6M
- PRTA 809.8M
- IPO Year
- EOI N/A
- PRTA N/A
- Fundamental
- Price
- EOI $20.09
- PRTA $7.18
- Analyst Decision
- EOI
- PRTA Buy
- Analyst Count
- EOI 0
- PRTA 9
- Target Price
- EOI N/A
- PRTA $51.71
- AVG Volume (30 Days)
- EOI 83.6K
- PRTA 1.6M
- Earning Date
- EOI 01-01-0001
- PRTA 05-08-2025
- Dividend Yield
- EOI 7.19%
- PRTA N/A
- EPS Growth
- EOI N/A
- PRTA N/A
- EPS
- EOI N/A
- PRTA N/A
- Revenue
- EOI N/A
- PRTA $137,935,000.00
- Revenue This Year
- EOI N/A
- PRTA N/A
- Revenue Next Year
- EOI N/A
- PRTA $122.59
- P/E Ratio
- EOI N/A
- PRTA N/A
- Revenue Growth
- EOI N/A
- PRTA 54.55
- 52 Week Low
- EOI $14.36
- PRTA $8.00
- 52 Week High
- EOI $18.88
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- EOI 67.80
- PRTA 30.36
- Support Level
- EOI $19.87
- PRTA $6.47
- Resistance Level
- EOI $20.16
- PRTA $8.08
- Average True Range (ATR)
- EOI 0.30
- PRTA 0.72
- MACD
- EOI 0.15
- PRTA 0.00
- Stochastic Oscillator
- EOI 96.13
- PRTA 21.60
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).